Author:
Ravanbakhsh Siamak,Gajewski Melissa,Greiner Russell,Tuszynski Jack A
Abstract
Abstract
Background
As microtubules are essential for cell growth and division, its constituent protein β-tubulin has been a popular target for various treatments, including cancer chemotherapy. There are several isotypes of human β-tubulin and each type of cell expresses its characteristic distribution of these isotypes. Moreover, each tubulin-binding drug has its own distribution of binding affinities over the various isotypes, which further complicates identifying the optimal drug selection. An ideal drug would preferentially bind only the tubulin isotypes expressed abundantly by the cancer cells, but not those in the healthy cells. Unfortunately, as the distributions of the tubulin isotypes in cancer cells overlap with those of healthy cells, this ideal scenario is clearly not possible. We can, however, seek a drug that interferes significantly with the isotype distribution of the cancer cell, but has only minor interactions with those of the healthy cells.
Methods
We describe a quantitative methodology for identifying this optimal tubulin isotype profile for an ideal cancer drug, given the isotype distribution of a specific cancer type, as well as the isotype distributions in various healthy tissues, and the physiological importance of each such tissue.
Results
We report the optimal isotype profiles for different types of cancer with various routes of delivery.
Conclusions
Our algorithm, which defines the best profile for each type of cancer (given the drug delivery route and some specified patient characteristics), will help to personalize the design of pharmaceuticals for individual patients. This paper is an attempt to explicitly consider the effects of the tubulin isotype distributions in both cancer and normal cell types, for rational chemotherapy design aimed at optimizing the drug’s efficacy with minimal side effects.
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Modelling and Simulation
Reference40 articles.
1. Jordan M, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Canc. 2004, 4: 253-265. 10.1038/nrc1317.
2. Rowinsky E, Burke P, Karp J, Tucker R, Ettinger D, Donehower R: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Canc Res. 1989, 49: 4640-4647.
3. Dutcher S: The tubulin fraternity: alpha to eta. Curr Opin Cell Biol. 2001, 13: 49-54. 10.1016/S0955-0674(00)00173-3.
4. Hyams J, Stebbings H: The mechanism of microtubule associated cytoplasmic transport. Isolation and preliminary characterisation of a microtubule transport system. Cell Tissue Res. 1979, 196: 103-116.
5. Pichichero M, Avers C: The evolution of cellular movement in eukaryotes: the role of microfilaments and microtubules. Subcell Biochem. 1973, 2: 97-105. 10.1007/BF01738683.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献